The most frequent genetic alteration in human
cancer is TP53 mutation. TP53 mutation in breast cancer
is linked to more aggressive disease and the worst overall
survival rate. Compared to other solid tumours, breast
cancer has a lower mutation frequency. Breast cancer
treatment may benefit from molecular pathological
analysis of the structure and expression of the TP53
pathway's components for diagnosis, prognostic
evaluation, and, ultimately treatment. In some studies, the
TP53 mutation has been linked to a good prognosis, while
in other studies, it has been linked to a poor prognosis.
The fact that the studies were conducted on various
tumour types and with various therapy regimens may be
the cause of these disparate results. The apoptosis, cell
cycle arrest, and senescence in response to stress are the
main topics of this review of recent developments in TP53
research. We also go over TP53-prevalence, prognosis
and detection of the mutation for treating human cancer.
Methods: Literature review of English language papers
available through PubMed and Google Scholar.
TP53, Breast Cancer, Mutation, Mutant P53, Human Cancers.